Paraneoplastic neurological therapy

Cancer patients often develop symptoms from organs remote from the primary tumor. The symptoms are usually caused by metastasis or toxic effects of therapy and less often by such secondary factors as nutritional deficiency, metabolic disturbances, opportunistic infections, and effects of critical illness. Other systemic diseases such as diabetes or amyloid may become manifest or aggravated during the course of the cancer disease and cause symptoms from remote organs. Paraneoplastic neurological syndromes (PNS) are a rare cause of remote symptoms [1]. The PNS affect less than 1% of all cancer patients [2], Even in small cell lung cancer (SCLC), the tumor type most commonly associated with PNS, these disorders occur in less than 5% of the patients [3, 4],... 

Voltz R. Paraneoplastic neurological syndromes An update on diagnosis, pathogenesis, and therapy. Lancet Neurol 2002 1(5) 294—305. 

Grisold W, Drlicek M, Liszka-Setinek U, Wondrusch E. Anti-tumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 1995 97(1) 106-111. 

Cher LM, Hochberg FH, Teruya J, Nitschke M, Valenzuela RF, Schmahmann JD, et al. Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorption. Cancer 1995 75(7) 1678—1683. 

Blaes F, Strittmatter M, Merkelbach S, Jost V, Klotz M, Schimrigk K, et al. Intravenous immunoglobulins in the therapy of paraneoplastic neurological disorders. J Neurol 1999 246(4) 299-303. 

Croteau D, Owainati A, Dalmau J, Rogers LR. Response to cancer therapy in a patient with a paraneoplastic choreiform disorder. Neurology 2001 57(4) 719-722. 

---